Trial Profile
A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 21 Jul 2023 Planned primary completion date changed from 23 Jul 2023 to 23 Jul 2024.
- 05 Dec 2019 Planned End Date changed from 6 Dec 2019 to 23 Jul 2024.
- 05 Dec 2019 Planned primary completion date changed from 6 Dec 2019 to 23 Jul 2023.